Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study to Evaluate Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Non-smokers (refrained from any tobacco or nicotine usage, including smokeless tobacco, nicotine patches, etc.) for at least 6 months prior to Day 1 of the study~2. Body Mass Index of 19 through 40 kg/m2~3. Participants must be willing to follow dietary restrictions~4. Females of childbearing potential (ie, not menopausal, no hysterectomy, no bilateral oophorectomy) must complete a negative pregnancy test (urine) prior to receiving any radioisotopes~5. No evidence of pelvic floor dysfunction~6. If clinically indicated, absence of an evacuation disorder should be confirmed within 30 days prior to the first dose of study medication~7. At Screening, patients must meet ROME III Criteria for FC, which assumes an absence of a structural or biochemical explanation~8. The patient's screening (baseline) colonic transit test must show a GC ≤ 2.4 at 24 hours; and~9. Baseline EKG shows QTc interval ≤ 450mSec~Exclusion Criteria:~1. History of clinically-significant manifestations or current abnormality of any organ system~2. History of inflammatory bowel disease~3. Any history of GI surgery within 6 months prior to the first dose of study medication~4. History of clinically-significant prolonged diarrhea, in the absence of a laxative~5. Patients who have started a special dietary habit and/or an intense physical workout program within 4 weeks prior to the first dose of study medication~6. Any clinically-significant surgical procedure within 30 days prior to the first dose of study medication~7. History of alcoholism or drug addiction within 12 months prior to the first dose of study medication~8. Any patient who has had an acute illness within 5 days prior to the first dose of study medication, eg, flu syndrome, GI virus, indigestion~9. Patients who are breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Capsule (Type: PLACEBO_COMPARATOR): Placebo Capsules
- YKP10811 Drug Product Capsule, 10 mg (Type: ACTIVE_COMPARATOR): None
- YKP10811 Drug Product Capsule, 20 mg (Type: ACTIVE_COMPARATOR): None
- YKP10811 Drug Product Capsule, 30 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).